ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
6.32
-0.08 (-1.25%)
Jan 27, 2023, 4:00 PM EST - Market closed
Stock Price Forecast
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SPRY stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '22 | Jan '23 |
---|---|---|
Strong Buy | 0 | 3 |
Buy | 0 | 3 |
Hold | 3 | 1 |
Sell | 1 | 0 |
Strong Sell | 2 | 0 |
Total | 6 | 7 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.11
from -2.56
EPS Next Year
-2.21
from -2.11
Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|---|
Revenue
|
- | - | - | - | - | - | - | 144.89M | 218.69M |
Revenue Growth
|
- | - | - | - | - | - | - | - | 50.94% |
EPS
|
-29.11 | -36.27 | -11.33 | -2.56 | -2.11 | -2.21 | -2.25 | -0.08 | 0.46 |
EPS Growth
|
- | - | - | - | - | - | - | - | - |
No. Analysts | - | - | - | - | 4 | 4 | 4 | 4 | 3 |
Revenue Forecast
Revenue | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 172.6M | 225.1M |
Avg | n/a | n/a | n/a | 144.9M | 218.7M |
Low | n/a | n/a | n/a | 117.3M | 210.1M |
Revenue Growth
Revenue Growth | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
High | - | - | - | - | 55.4%
|
Avg | - | - | - | - | 50.9%
|
Low | - | - | - | - | 45.0%
|
EPS Forecast
EPS | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
High | -2.17 | -2.28 | -2.32 | -0.05 | 0.47 |
Avg | -2.11 | -2.21 | -2.25 | -0.08 | 0.46 |
Low | -2.03 | -2.13 | -2.17 | -0.11 | 0.44 |
EPS Growth
EPS Growth | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.